Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials | Lupus Science & Medicine

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Archive

Authors

About

Podcasts
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF +
Supplementary
Material

XML

Clinical trials and drug discovery

Original research

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

Online download statistics by month:

Online download statistics by month: February 2021 to April 2023

	Abstract	Full	Pdf
Feb 2021	638	638	166
Mar 2021	422	420	140
Apr 2021	313	304	86
May 2021	410	405	149
Jun 2021	369	364	118
Jul 2021	341	335	77
Aug 2021	451	447	153
Sep 2021	322	314	114
Oct 2021	328	325	102
Nov 2021	347	342	122
Dec 2021	273	267	79
Jan 2022	232	236	80
Feb 2022	230	223	85
Mar 2022	332	331	89
Apr 2022	274	264	76
May 2022	292	286	93
Jun 2022	231	223	79
Jul 2022	154	153	38
Aug 2022	209	201	73
Sep 2022	211	200	75
Oct 2022	169	162	50
Nov 2022	200	192	72
Dec 2022	110	101	51
Jan 2023	163	149	53
Feb 2023	262	250	64
Mar 2023	208	195	57
Apr 2023	262	258	101
Total	7753	7585	2442